Beyond TB, SMASH’s adaptability can facilitatethe detectionof clinically significant mutations in other genetic hotspots linkedto disease susceptibility.−,  For instance, TP53 mutations are associated with malignant progression and chemoresistance,, while gyrA mutations contribute to drug resistancein bacterial pathogens, such as corynebacteria and . By facilitating the targeted screeningof these regions, SMASH has the potential to deepen our understandingof disease etiology, refine therapeutic and diagnostic strategies,and support the advancement of personalized medicine. The gene discussed is TP53; the disease is tuberculosis.